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Genetic Testing
in Brugada Syndrome*
Elizabeth S. Kaufman, MD
Cleveland, Ohio
Brugada syndrome (BrS) is a hereditary arrhythmic disorder
associated with a right ventricular conduction delay and
ST-segment elevation in the right precordial leads and
syncope and sudden death due to ventricular fibrillation (1).
The type 1 Brugada electrocardiographic ECG pattern
(coved ST-segment elevations in leads V1 to V3) is a
ynamic finding that may be present at baseline or may
ecome apparent only under certain conditions (such as
ever, vagal stimulation, or exposure to a sodium channel
locking drug) (2,3). In fact, administration of a sodium
hannel blocking drug is used to clarify the diagnosis when
rS is suspected but the presenting electrocardiogram does
ot show a type 1 BrS pattern. The clinical diagnosis of BrS
s made when a type 1 BrS ECG pattern (spontaneous or
rug-induced) occurs in association with a personal history
f syncope or aborted sudden cardiac death or in association
ith a family history of type 1 BrS ECG or sudden cardiac
eath (4). High-risk patients with BrS, such as those who
ave experienced an episode of cardiac arrest or syncope, are
reated with an implantable cardioverter-defibrillator.
See page 1410
Lower-risk patients undergo various attempts at clinical risk
stratification, a process about which there remains consid-
erable uncertainty. Those patients who do not receive
implantable defibrillators nevertheless receive close clinical
follow-up, counseling about which drugs to avoid, and
advice about screening of family members (4). With regard
to family screening, genetic testing can be particularly useful
because discovery of a probable disease-causing mutation in
a proband can aid in identifying affected and unaffected
family members.
Although multiple genetic causes of BrS have been
identified, BrS is most often (15% to 30% of the time)
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Medical.caused by mutations in SCN5A that cause loss of function in
the sodium channel INa (5–7). Whether all patients with
uspected BrS should undergo genetic testing is not known,
or is there agreement on whether genetic testing should
outinely include genes beyond SCN5A. The study by Crotti
t al. (8) in this issue of the Journal helps to address these
aps in our knowledge. The investigators performed genetic
esting for 12 BrS susceptibility genes in 129 unrelated,
rimarily Caucasian patients with either clinically diagnosed
rS or a type 1 BrS ECG pattern. They discovered likely
utations in 27 patients (21%), and of these, 21 patients
78%) had mutations in SCN5A. Although the yield of
enetic testing was only 21% overall, the investigators found
much higher yield in various subpopulations. In male
atients, the yield ranged from 11% in those 40 years of
ge to 21% in male patients 20 to 40 years of age, and to
0% in male patients20 years of age. Another group likely
o have SCN5A mutations were those with PQ (PR)
ntervals 200 ms, in whom the yield was 39%, compared
ith 8% in those with a PQ interval200 ms. Interestingly,
t did not matter whether patients had clinical evidence of
rS or merely the ECG pattern of BrS—the yield was as
igh in those who simply had abnormal ECG findings.
From these results, the authors draw several conclusions.
ased on their important finding of a high yield from
enetic testing in patients with an isolated BrS ECG
attern, the authors recommend genetic testing in these
ndividuals in addition to those with clinical BrS. These
ecommendations concur with the position paper of the
anadian Cardiovascular Society/Canadian Heart Rhythm
ociety (9) but not with the consensus statement of the
eart Rhythm Society/European Heart Rhythm Associa-
ion (10). Based on their finding of a low prevalence of
on-SCN5Amutations, the authors suggest that it would be
easonable to test most patients for SCN5Amutations alone,
with further testing for the minor BrS genes only in special
circumstances. As an example of phenotype-guided genetic
analysis, testing for calcium channel–mediated BrS, known
to cause BrS and a short QT interval (11), could be reserved
for patients with short QT intervals.
A few caveats apply to this study. First, it was performed
in a largely (95%) Caucasian population, and the distribu-
tion of mutations may be quite different in other ethnic
groups, such as the East Asian population, in whom BrS is
more prevalent. Second, and more importantly, it is not
always clear which genetic variants should be classified as
potentially disease-causing mutations. The investigators
used a restrictive definition of a mutation as a nonsynony-
mous variant that was absent in at least 1,400 ethnically
matched reference alleles and all publicly available data-
bases. Further, the authors point out that although rare
missense variants in SCN5A are found in 2% to 4% of
apparently healthy controls, none of the mutations that they
identified were located in the low-probability (of causing
disease) regions where most apparently harmless polymor-
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it is likely that the mutations were, in fact, disease causing.
The drawback of using such a strict, high-specificity defi-
nition of a mutation is that some disease-causing mutations
may have been missed. Indeed, in addition to the reported
mutations, the investigators also detected uncommon ge-
netic variants in 13 additional patients, including some
variants that have been associated functionally or clinically
with BrS or related disorders. The investigators chose not to
consider these variants as potentially disease-causing muta-
tions on the basis of their presence in healthy controls. If the
authors had included these variants, the results would have
looked quite different, with an overall mutation detection
yield of 31%, of which only 58% were SCN5A mutations.
xtending routine genetic testing beyond SCN5A would
etect more of these possibly important variants, increasing
he sensitivity of the test. The authors argue that reporting
hese variants would lead to confusion because some of these
ariants are not associated with disease. However, for the
linician orchestrating the screening and care of BrS pa-
ients and their families, information about variants that are
ossibly disease causing may be helpful when interpreted
autiously and in a clinical context. Decisions about risk
tratification and management of patients at risk of BrS are
lready fraught with complexity. The clinicians who make
hese decisions are accustomed to managing uncertainty and
eed to rely on as many clues, clinical and genetic, as
ossible.
In conclusion, Crotti et al. (8) demonstrated the preva-
ence of SCN5A and non-SCN5A mutations in a Caucasian
opulation of BrS probands. They confirmed the value of
esting patients with an isolated BrS ECG pattern. Further,
hey stressed the importance of tailoring genetic testing to
he clinical phenotype. Although future studies will need to
ssess the distribution of mutations in other, non-Caucasian
opulations and to probe the clinical significance of rare
enetic variants, the study by Crotti et al. (8) has advanced
ur understanding of the genetic basis of BrS and should
elp inform future recommendations about genetic testing
n suspected BrS patients. sReprint requests and correspondence: Dr. Elizabeth S. Kauf-
man, Heart and Vascular Research Center, Hamann 3rd Floor,
MetroHealth Campus, Case Western Reserve University, 2500
MetroHealth Drive, Cleveland, Ohio 44109-1998. E-mail:
ekaufman@metrohealth.org.
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